Aurora kinase A (AURKA)

Overview

Aurora kinase A (AURKA) is a serine/threonine kinase encoded by the AURKA gene and is a critical regulator of mitotic progression in mammalian cells. It localizes to the centrosome and mitotic spindle, where it orchestrates centrosome maturation, bipolar spindle assembly, and accurate chromosomal segregation during cell division. Beyond its canonical mitotic functions, AURKA participates in a range of non-mitotic processes including DNA damage response, regulation of transcription factor activity, and cellular stress adaptation. Dysregulation of AURKA — most commonly through gene amplification or protein overexpression — is observed across a broad spectrum of human malignancies, including breast, colorectal, head/neck, melanoma, ovarian, liver, and prostate tumors, establishing it as both an oncogenic driver and a high-priority therapeutic target.

Structurally, AURKA contains an N-terminal regulatory domain and a C-terminal catalytic kinase domain. Its activity is tightly controlled through phosphorylation at Thr288 and interaction with co-activators such as TPX2. In oncological contexts, AURKA overexpression promotes tumor progression through multiple mechanisms: driving genomic instability, sustaining proliferative signaling via pathways including PI3K/AKT/mTOR, suppressing tumor suppressors such as PTEN, and interacting with oncoproteins such as MYCN. This multifaceted oncogenic role, combined with its well-defined ATP-binding pocket, has made AURKA an attractive focus for small-molecule inhibitors and, more recently, targeted protein degradation strategies.

Recent Publications Summary

Recent studies have continued to position Aurora kinase A (AURKA) as a therapeutically important mitotic regulator and a target for both inhibitor-based and degradation-based strategies in cancer. Several groups used PROTAC or hydrophobic-tag approaches to overcome limitations of conventional ATP-competitive inhibitors, including poor subtype selectivity and incomplete suppression of noncatalytic functions. A highly subtype-selective AURKA PROTAC degrader, CT3, showed stronger antiproliferative activity than its parental inhibitor in Jurkat cells and produced antitumor effects in Jurkat xenograft models 42466758Jul. In parallel, another study identified M9101 as a potent, selective, and in vivo active AURKA degrader with a DC50 of 2.3 nM in MD-MBA-231 cells and strong global proteomic selectivity, while a broader hydrophobic-tag profiling effort mapped degradable kinases across the human kinome and included optimized AURKA degraders among the validated examples 42214088May42007494Apr.

Mechanistic work has also expanded understanding of AURKA biology beyond its canonical mitotic role. One study found that AURORA A interacts with DICER and SETD2 during S-phase, revealing a non-catalytic scaffolding function and suggesting that AURORA A helps organize RNA-dependent complexes involved in R-loop processing and chromatin regulation 42380670Jul. These findings help explain why AURKA depletion by PROTACs can produce profound S-phase defects rather than only G2/M arrest 42380670Jul. In a related line of work, AURKA was linked to radioresistance in pancreatic ductal adenocarcinoma through interaction with GSK-3β and inhibitory phosphorylation of PTEN at T366, with downstream sustained activation of the PI3K/AKT/mTOR pathway implicated in the resistant phenotype 41864259Mar.

AURKA has also been studied in combination strategies aimed at improving anticancer efficacy. In prostate cancer, the AURKA inhibitor VIC-1911 induced mitotic defects, DNA double-strand breaks, and a functional BRCAness state that sensitized cells and xenografts to PARP inhibition 41915443Mar. In Rb-deficient Cancers, dual targeting of TRIP13 and AURKA caused prolonged mitotic arrest, mitotic DNA damage, and concurrent apoptotic and GSDME-mediated pyroptotic cell death, supporting a cooperative role for AURKA inhibition in driving lethal mitotic stress 42013305Apr. Bioinformatics and network pharmacology studies also continued to identify AURKA as a hub target in multi-cancer analyses, including breast, ovarian, and colorectal cancer signatures and hepatocellular carcinoma datasets, where it emerged among the top candidate targets for multitarget therapeutic development 42224282Jun42145839May.

Beyond direct tumor-cell effects, AURKA has been implicated in tumor-immune interactions. In non-small-cell lung cancer models, elevated Aurora A expression was associated with reduced responses to immune checkpoint blockade, and mechanistic experiments showed that Aurora A overexpression promoted T-lymphocyte apoptosis through exosomal miR-644a and the NOXA/p4E-BP1/MCL1 axis 42203488May. Together, these publications portray AURKA as a multifaceted cancer target whose inhibition or degradation can affect mitosis, S-phase genome maintenance, DNA repair, radioresponse, and immune evasion, while also highlighting the growing interest in selective degraders and rational combination therapies 42466758Jul42380670Jul42214088May41915443Mar42013305Apr41864259Mar42203488May.

What Changes, What Holds

1. Selective degradation now looks more promising than inhibition for AURKA targeting
REINFORCES CT3, M9101, and the hydrophobic-tag work do not revise the baseline view of AURKA as a druggable oncogenic kinase; they sharpen it by showing that removing the protein can outperform simply blocking its ATP site. That matters because the baseline already flags incomplete suppression of noncatalytic functions as a limitation of conventional inhibitors. The new studies strengthen the case for degrader-based strategies, but they remain preclinical and do not yet establish superiority in patients. 42466758Jul42214088May

2. AURKA has a noncatalytic S-phase role that helps explain why depletion can be more disruptive than mitotic arrest alone
NEW DIRECTION AURKA is no longer best understood only as a mitotic kinase acting at centrosomes and the spindle; the new work adds a scaffolding function in S phase that the Overview does not cover. That expands its biology into RNA-dependent complex organization, R-loop processing, and chromatin regulation, and it helps reconcile why PROTAC-mediated loss can trigger S-phase defects rather than just G2/M arrest. The radioresistance/PTEN finding also extends the oncogenic network, but the main change is the added nonmitotic role. 42380670Jul41864259Mar

3. AURKA inhibition may create exploitable DNA-repair defects and lethal mitotic stress in combination regimens
REINFORCES These studies do not overturn the baseline’s oncogenic framing; they extend it by showing how AURKA blockade can be paired with other therapies to intensify tumor killing. The prostate and Rb-deficient cancer findings support the idea that AURKA contributes to genomic instability and survival signaling, and that inhibiting it can expose vulnerabilities in DNA repair and mitotic control. The practical implication is combination design, not a new core biology. 41915443Mar42013305Apr

4. AURKA may also shape immune evasion, which broadens its relevance beyond tumor-cell proliferation
NEW DIRECTION Elevated Aurora A is now linked to impaired response to checkpoint blockade and to T-cell apoptosis, a role the Overview does not mention. That does not contradict its established mitotic or oncogenic functions, but it adds a tumor-immune dimension that could matter for treatment selection and resistance. The evidence is still mechanistic and model-based, so the immune effect should be treated as provisional until it is validated across additional systems and clinical settings. 42203488May

Overview update candidates: AURKA’s noncatalytic S-phase scaffolding role; its potential contribution to tumor immune evasion; and the growing therapeutic relevance of degrader-based strategies.